Calidi Biotherapeutics, Inc. 8-K

What Happened

• On May 14, 2026, Calidi Biotherapeutics, Inc. (CLDI) announced and furnished a press release reporting certain results of operations and financial condition for the quarter ended March 31, 2026. The press release is included as Exhibit 99.1 to the Form 8‑K. The filing also contains Regulation FD disclosure regarding the same information.

Key Details

• Filing date: May 14, 2026 (Form 8‑K).
• Period reported: Quarter ended March 31, 2026 (Q1 2026).
• Press release furnished as Exhibit 99.1 to the 8‑K.
• Company included Regulation FD disclosure (Item 7.01) to broadly announce the information.

Why It Matters

• This filing provides the company’s latest quarterly results and corporate developments, which investors use to evaluate near‑term financial performance (earnings, revenue, cash position) and business progress.
• The Regulation FD disclosure means the company made the information broadly available to the market to prevent selective disclosure, supporting fair access to material updates.
• The 8‑K does not report executive changes, mergers/acquisitions, or bankruptcy events; it is focused on public release of quarterly financial information.